Skip to content

Assessing Neurovirulence and Neurotoxicity of Novel Viral Vector Platforms

Learn how we assess neurovirulence and neurotoxicity for responsible development of viral-based medicines.

The rapid development of viral vector platforms for gene therapy and vaccines holds immense potential for treating various diseases. However, as witnessed in the past, inadequate safety characterization can have devastating consequences. To ensure the safe and responsible development of these therapeutics, thorough neurovirulence and neurotoxicity testing is crucial.

Get This Resource


To access, please fill out and submit the adjacent form.

Cover: Assessing Neurovirulence and Neurotoxicity of Novel Viral Vector Platforms
Assessing Neurovirulence and Neurotoxicity of Novel Viral Vector Platforms
Name
Therapeutic Areas: IDR

Ready to Advance Your Research?

Contact our experts today and explore how Southern Research can elevate your project.